SPECT/CT Image Guided Radiation Therapy for Prostate Cancer Clinical-Use Methods across Multiple Practice Settings:
Advances in molecular imaging and conformal radiation therapy have converged to enable more precise delivery of therapy to regions of known disease.  The recent publication of long-term prostate cancer outcome data, with dose escalation targeting  discrete areas of tumor identified with SPECT/CT, demonstrates advantages in biochemical disease free survival and lower rates of morbidity1-7.  Radiation Oncologist Rodney J. Ellis, a pioneer in conformal therapy outcome research using PSMA directed Capromab Pendetide, presents an update on image guided radiation therapy (IGRT) using SPECT/CT.  This evidence-based educational lecture provides a how-to review and applications of SPECT/CT tumor targeting techniques for use in brachytherapy, intensity modulated radiation therapy (IMRT) and other conformal therapies for prostate cancer; as a case example of the new applications of molecular imaging in radiation oncology. 

This presentation will require the use of a PowerPoint Viewer or Flash Plug-in in order to launch the presentation. If you do not have these viewers you may obtain it here:
Microsoft Office Downloads: Viewers for PowerPoint 2003
Adobe Flash Plug-in: Viewer for Flash media

1. Click here to access the PowerPoint presentation. This download could take an hour or longer depending on your connection speed as the file is 70MB.
2. You may access the Flash presentation by clicking here. Access time should be much faster

1. Ellis RJ et al.  Feasibility and acute toxicity of radioimmunoguided prostate brachytherapy. Int J Radiation Oncology, Biology, Physics. 2000;48(3):681-685.
2. Ellis RJ et al. Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2003;57:362-70.
3. Ellis RJ et al. Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. Brachytherapy 2003;2:215-22.
4. Ellis RJ et al. Seven-year biochemical disease-free survival rates following
    permanent prostate brachytherapy with dose escalation to biological tumor volumes
    identified with SPECT/CT fusion brachytherapy. Brachytherapy. 2005;4(2):107P-88.
5. Ellis RJ et al.  Rectal morbidity following permanent prostate brachytherapy with dose escalation to biological target volumes identified with SPECT/CT image fusion. Brachytherapy 2005;4(2):1110P-91.
6. Ellis, RJ et al. SPECT/CT Capromab Pendetide Independently predicts bDFS in long term outcome study [Abstract]. J Urology 2006 May; P-91131 (in press).
7. Ellis RJ et al. Translation of SPECT/CT guided prostate brachytherapy to a community setting from the university setting with a case example of histopathologic correlation to the image set. J Nuc Med. 2005;46 (Supplement 2):1422-3(P-1423).